Company news
Soligenix, Inc. (NASDAQ:SNGX) news
Soligenix, Inc. news releases on 6ix. Latest, Jun 8, 2026: Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
Press releases & updates
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
June 8, 2026
Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo
May 26, 2026
Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
May 8, 2026
Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
April 27, 2026
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
April 1, 2026
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
March 30, 2026
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
March 25, 2026
Soligenix (SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
March 24, 2026
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
March 22, 2026
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
March 18, 2026
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
March 9, 2026
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
February 26, 2026
Soligenix to Present at BIO Investment & Growth Summit
February 24, 2026
Soligenix Details Recent Progress and Upcoming Milestones
February 12, 2026
SNGX: Positive Results for Phase 2a Trial in Psoriasis
December 22, 2025
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
December 18, 2025
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
December 17, 2025
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
December 5, 2025
SNGX: Phase 3 FLASH2 Trial Enrolls 50th Patient; Interim Analysis in 2Q26
November 20, 2025
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
November 19, 2025
SNGX: DMC Reports No Safety Signals for Ongoing Phase 3 Trial in CTCL; Blinded Interim Efficacy Analysis in 1H26
November 10, 2025
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
November 7, 2025
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
October 14, 2025
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
October 7, 2025
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
September 30, 2025
Soligenix Announces Closing of $7.5 Million Public Offering
September 29, 2025
Soligenix Announces Pricing of $7.5 Million Public Offering
September 26, 2025
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
September 23, 2025
Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses
September 4, 2025
Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
SNGX: Dusquetide (SGX945) Granted Orphan Drug Designation for Behcet’s Disease
August 20, 2025
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
August 18, 2025
Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
August 14, 2025
NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer
August 8, 2025
Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy
August 7, 2025
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
August 4, 2025
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease
July 31, 2025
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
July 8, 2025
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
July 1, 2025
Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
June 5, 2025
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
May 9, 2025
Soligenix Issues Interim Results For CTCL Treatment Trial 75% Response At 18 Weeks, 3 Patients Achieve Complete Response
May 4, 2025
Soligenix's HyBryte(TM) Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding
April 23, 2025
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
April 14, 2025
Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants
March 25, 2025
Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results
March 21, 2025
HyBryte™ Treatment Studies Presented at Two Medical Conferences in March
March 6, 2025
Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behcet's Disease
February 20, 2025
Soligenix to Present at BIO CEO & Investor Conference
February 3, 2025
Soligenix Targets Psoriasis With New Therapy
January 16, 2025